alexmillos / Shutterstock.com
As India appears to forge closer trade relations with the US, will the country introduce a data exclusivity legal provision and what impact would this have? LSIPR investigates.
India is one of the world’s largest suppliers of generic drugs, with its plants estimated to manufacture 40% of all generic medicines in the US and 90% of the world’s generic HIV/AIDS medicines. But its approach to intellectual property has sometimes riled innovator companies—and in recent years, businesses including Gilead and Novartis been refused Indian patents for products that are IP-protected in other countries.
Meanwhile, Bayer has been engaged in a long battle to revoke a compulsory licence that lets Indian generic drug makers make and sell the patent-protected cancer drug Nexavar (sorafenib).
Now, big pharma companies are looking for alternative ways to protect their products in the subcontinent—through data exclusivity.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Gilead, Novartis, data exclusivity, WTO, TRIPS, USTR,
